New research out of VCU Massey Cancer Center suggests that the inactivation of NF1—a gene known as Neurofibromin-1 that holds natural tumor-suppressing functions—could be instrumental in the onset of pancreatic cancer, either in tandem with KRAS mutations, which occur in 85-90% of all pancreatic tumors, or even before any mutations occur in the KRAS gene, in partnership with TP53, the most inactivated tumor suppressor gene in human malignancies.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe